Tepoditamab - CAS 2044679-53-8

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1].

Integrin

Cytoskeletal Signaling

2044618

-20°C

Ice Packs

Inhibitory Antibodies